CaseBioscience (Private) Joins Programme to Reduce Cell-Therapy Cold-Chain Dependence
An ARPA-H-backed team will explore room-temperature preservation of living cellular medicines.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
CaseBioscience has announced its participation in a Likarda-led team awarded up to $7.3 million through ARPA-H's BioStabilization Systems programme. The project aims to develop methods for storing and transporting living cells at ambient temperature.
The announcement identifies an initial 15-month phase beginning on 24 September. Collaborators span cell preservation, engineering, formulation and manufacturing expertise. CaseBioscience will contribute work on clinical media, cellular metabolism and biopreservation.
The problem is commercially relevant because specialised temperature control can complicate distribution of cellular medicines. A reliable alternative could broaden the range of centres able to handle them and reduce some logistical burdens.
The award supports research into that possibility; it does not demonstrate a working replacement for existing storage requirements. Living cells must retain function as well as survive transport, and any new preservation process would need to be validated for its intended product. The project targets a potentially important manufacturing constraint, with the scientific and implementation challenges still ahead.